Drug Profile


Alternative Names: AMD 473; JM 473; NX 473; ZD 0473

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Johnson Matthey
  • Developer Poniard Pharmaceuticals
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Small cell lung cancer
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Mar 2012 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 30 Mar 2012 Discontinued - Phase-III for Small cell lung cancer (second-line therapy) in Chile (IV)
  • 30 Mar 2012 Discontinued - Phase-III for Small cell lung cancer (second-line therapy) in Argentina (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top